B. Riley Predicts Weaker Earnings for Trevi Therapeutics

Trevi Therapeutics, Inc. (NASDAQ:TRVI) – Equities research analysts at B. Riley dropped their Q2 2025 earnings per share (EPS) estimates for Trevi Therapeutics in a research note issued on Wednesday, March 19th. B. Riley analyst M. Mamtani now expects that the company will earn ($0.16) per share for the quarter, down from their previous estimate of ($0.14). B. Riley currently has a “Buy” rating and a $20.00 target price on the stock. The consensus estimate for Trevi Therapeutics’ current full-year earnings is ($0.49) per share. B. Riley also issued estimates for Trevi Therapeutics’ Q3 2025 earnings at ($0.17) EPS, Q4 2025 earnings at ($0.20) EPS, FY2025 earnings at ($0.69) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.95) EPS, FY2028 earnings at ($1.10) EPS and FY2029 earnings at ($1.17) EPS.

Other equities research analysts also recently issued reports about the company. Needham & Company LLC reduced their price target on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating on the stock in a report on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $21.00 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Oppenheimer increased their price objective on Trevi Therapeutics from $12.00 to $20.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. HC Wainwright reissued a “buy” rating and issued a $12.50 price objective on shares of Trevi Therapeutics in a research note on Wednesday. Finally, Raymond James raised Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $9.00 to $29.00 in a research note on Monday, March 10th. Seven analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $17.56.

Trevi Therapeutics Stock Performance

Shares of NASDAQ TRVI opened at $6.47 on Friday. The business’s 50 day moving average price is $4.60 and its 200-day moving average price is $3.75. Trevi Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $7.39. The company has a market cap of $497.32 million, a price-to-earnings ratio of -14.70 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last issued its quarterly earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.01.

Insider Buying and Selling at Trevi Therapeutics

In other Trevi Therapeutics news, insider Farrell Simon sold 81,313 shares of the stock in a transaction on Monday, March 10th. The stock was sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares of the company’s stock, valued at approximately $519,075. This trade represents a 51.39 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 24.37% of the company’s stock.

Institutional Trading of Trevi Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. boosted its position in Trevi Therapeutics by 84.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after acquiring an additional 2,894 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Trevi Therapeutics by 130.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after purchasing an additional 6,764 shares in the last quarter. Raymond James Financial Inc. acquired a new stake in shares of Trevi Therapeutics in the 4th quarter worth $49,000. Squarepoint Ops LLC acquired a new stake in shares of Trevi Therapeutics in the 4th quarter worth $58,000. Finally, Two Sigma Advisers LP acquired a new stake in shares of Trevi Therapeutics in the 4th quarter worth $66,000. Institutional investors own 95.76% of the company’s stock.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.